


Amendments to the Claims


Please amend Claims 1 and 3. The Claim Listing below will replace all prior versions of the Claims in the application:

Claim Listing

1. (Currently amended) A pharmaceutical composition comprising a unit dosage form ~~of an effective amount~~ of a polydiallylamine homopolymer, said homopolymer characterized in that the polymer is ~~substantially~~ free of alkylated amine monomers and a pharmaceutically acceptable carrier.
2. (Original) The pharmaceutical composition of Claim 1 wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
3. (Currently amended) The pharmaceutical composition of Claim 2 wherein the polymer is crosslinked using epichlorohydrin ~~said crosslinking agent comprises epichlorohydrin.~~
4. (Original) The pharmaceutical composition of Claim 1 wherein the polydiallylamine homopolymer is characterized by one or more monomeric units of the formulae:



(I)



(II)

or a combination thereof and salts thereof.

5. (Original) The pharmaceutical composition of Claim 4 wherein the monomeric units are in the free-base form.
6. (Original) The pharmaceutical composition of Claim 4 wherein the monomeric units are a salt or a partial salt.
7. (Previously presented) A pharmaceutical composition of Claim 1 wherein the unit dosage form is a tablet.
8. (Previously presented) A pharmaceutical composition of Claim 1 wherein the unit dosage form is a capsule.